市場調查報告書
商品編碼
649745

全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場:開發平台治療藥,診斷技術,治療方法,各地區 - 成長,趨勢,預測(2018年∼2023年)

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場在2018年到2023這段調查期間中,預測將以25.0%的年複合成長率成長。糖尿病及肥胖症的盛行率上升,研究開發的投資增加等,促進了該市場的成長。就各地區來看,新醫療技術的引進率高,高度優先於研究和開發活動的健全醫療保健基礎設施使得美國興起為最大市場。

本報告提供全球非酒精性脂肪性肝炎(NASH)市場調查,提供市場概要,各技術·用途·各地區的市場趨勢,市場規模的變化與預測,成長要素·阻礙因素以及市場機會·課題分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • NASH療法的利潤管道
    • 全球性糖尿病和肥胖人口的患病率上升
    • 新型生物標誌物技術的出現和肝活檢技術的改進
  • 阻礙因素
    • 缺乏非酒精性脂肪肝病(NAFLD)的有效診斷
    • 治療領域的技術進步停頓
  • 市場機會
  • 主要課題

第7章 非酒精性脂肪性肝炎(NASH)市場:各市場區隔

  • 開發平台治療藥物別
    • 第三階段試驗
      • 二乙酸(OCA)
      • Aramchol(花生酰胺膽鹼酸)
      • Saroglitazar
      • Elafibranor
      • 其他
  • 各診斷技術
    • 成像
    • 肝臟切片檢查
    • 生物標記診斷
    • 其他
  • 各治療法
    • 藥物療法
    • 胰島素抗性改善治療
    • 抗細胞因子治療
    • 外科手術
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭情形

  • 合併·收購分析
  • 協定·聯盟·合作
  • 新產品的上市

第9章 主要企業

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

第10章 市場未來展望

第11章 免責聲明

目錄
Product Code: 60469

The non-alcoholic steatohepatitis therapeutics and diagnostics market is anticipated to reach a CAGR of 25.89%, during the forecast period. The major factors driving the growth of the market studied are the increase in the NASH-affected population, the rising global prevalence of diabetic and obese populations, and the increasing awareness about NAFLD/NASH.

Currently, there are no FDA-approved therapies for NASH. Hence, there is a pressing need to find appropriate therapeutic targets for the treatment of NASH. However, the understanding of the pathogenesis and progression of NASH has evolved, and several promising novel therapies associated with the same are being evaluated. However, there is no specialized diagnostic test available in the market for NAFLD, and thus, the lack of effective diagnostic tests for non-alcoholic fatty liver disease, and the slow advancements in the therapeutics field have been limiting the growth of the market.

Key Market Trends

Diagnostic Tests in Diagnostics Segment Projected to Have Notable Market Growth

As there are limited specific diagnostic tests are available for the NASH, the lipid profile tests, liver function tests, and fibrosis assessment tests are commonly used diagnostic tests. NASH is diagnosed when examination of the tissue with a microscope shows fat along with inflammation and damage to liver cells. Furthermore, many of the in vitro diagnostic tests are planned to be released by the end of 2020, which may augment the growth rate.

Since liver-related mortality is increasing in developed markets, such as the United States, the companies are focusing more toward proper diagnostic tests, which can directly target the developed markets and benefit both, patients and the firm.​ For instance, OWL Metabolomics has developed OWLiver, non-invasive assay, to detect NASH, that use highly sensitive laboratory processes to determine the form of disease present in the patient's liver

In January 2019, Genfit took the first step toward making this test available, as it had signed a licensing agreement with LabCorp, leading drug development and NASH clinical trial company, to expand the access to NIS4 in the global clinical research community. The company is planning to market its IVD test for NASH, as a laboratory developed test (LDT), in 2019. Furthermore, it is planning to submit the same for FDA marketing authorization, in 2020.​ Hence, owing to aforementioned factors and growing burden of risk factors such as obesity is fulling the market for diagnostic tests expected to have significant growth over forecast period,​

North America Dominates the NASH Therapeutics and Diagnostics Market

The North American market is expected to grow due to the increasing prevalence of non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease (steatohepatitis) is considered as the most common form of chronic liver disease. According to a study conducted by the Intermountain Healthcare researchers, on the economic impact of the disease, the non-alcoholic fatty liver disease affects approximately 100 million Americans every year, and the cost of the disease impacting the US healthcare system is nearly USD 32 billion, annually.

Another driving factor is the rising number of obese patients in the country. For instance, as per OECD data, 47% of the adult population in the United States may suffer from obesity by 2030, as compared to 37.7% in 2014. This represents an estimated 25% increase in obesity, by 2030. Therefore, with an increasing number of obese patients, the usage of diagnostics and therapeutics is also expected to rise in the future.

Competitive Landscape

Several major players, such as Galmed, Intercept, Genfit, and OWL Metabolomics are among others, have their NASH drugs in the last stage of clinical trials. Moreover, there has been an increasing demand for advanced diagnostics, as there are very limited tests available in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in NASH-affected Population
    • 4.2.2 Rising Global Prevalence of Diabetic and Obese Populations
    • 4.2.3 Increasing Awareness about NAFLD/NASH
  • 4.3 Market Restraints
    • 4.3.1 Lack of Effective Diagnostics for Non-alcoholic Fatty Liver Disease (NAFLD)
    • 4.3.2 Slow Advancements in the Therapeutic Field
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Therapeutics
    • 5.1.2 Diagnostics
      • 5.1.2.1 Imaging Techniques
      • 5.1.2.2 Diagnostic Tests
      • 5.1.2.3 Biopsy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc. (Allergan PLC)
    • 6.1.2 Novartis AG
    • 6.1.3 Quest Diagnostics
    • 6.1.4 Exalenz Bioscience Ltd.
    • 6.1.5 Intercept Pharmaceuticals Inc.
    • 6.1.6 Gilead Sciences Inc.
    • 6.1.7 Genfit SA
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Zydus Cadila
    • 6.1.10 Merck & Co.
    • 6.1.11 OWL metabolomics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS